US Broker Ratings

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Deep Dive into Potential 55% Upside

Amylyx Pharmaceuticals, Inc. (AMLX) presents a compelling opportunity for investors with its focus on developing innovative treatment options for neurodegenerative diseases. Despite its clinical-stage status, the..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 27.68% Potential Upside and Robust Revenue Growth

Investors scanning the healthcare landscape for promising opportunities might find Xeris Biopharma Holdings, Inc. (XERS) a compelling prospect. Positioned in the specialty and generic drug manufacturing..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A Promising 191.67% Potential Upside Amidst Pioneering Biotech Innovations

Investors keeping a close eye on the biotechnology sector should take note of Gyre Therapeutics, Inc. (NASDAQ: GYRE), a burgeoning player in the healthcare industry renowned..

RxSight, Inc. (RXST) Stock Analysis: Exploring a Potential 62% Upside in the Medical Devices Sector

RxSight, Inc. (NASDAQ: RXST), a key player in the healthcare sector’s medical devices industry, has been catching investor attention with its innovative approach to cataract surgery...

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Investors Eye a Potential 103.8% Upside in CRISPR Pioneer

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a trailblazer in the realm of genome editing with its CRISPR/Cas9-based technologies, stands at an intriguing crossroads for investors. The Cambridge,..

Cogent Biosciences, Inc. (COGT): Investor Outlook with 89% Potential Upside

Cogent Biosciences, Inc. (NASDAQ: COGT) stands at the forefront of precision therapies targeting genetically defined diseases. As a clinical-stage biotechnology company, Cogent’s innovative approach has captured..

Castle Biosciences, Inc. (CSTL) Stock Analysis: A Look at Its 33.79% Potential Upside

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the diagnostics and research industry within the healthcare sector, is capturing the attention of investors with a..

Arcus Biosciences (RCUS) Stock Analysis: Unveiling a 75% Potential Upside Amidst Biotech Challenges

Arcus Biosciences, Inc. (NASDAQ: RCUS) presents a compelling narrative in the biotechnology sector, capturing investor attention with a remarkable potential upside of 75.28%. This clinical-stage biopharmaceutical..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring an 824% Potential Upside in Biotech

For investors with an appetite for risk and a keen interest in the biotechnology sector, Upstream Bio, Inc. (NASDAQ: UPB) presents an intriguing opportunity. Despite its..

Tilray Brands, Inc. (TLRY) Stock Analysis: Exploring a Potential 83% Upside in the Cannabis Sector

Tilray Brands, Inc. (NASDAQ: TLRY) is a prominent player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Headquartered in Leamington, Canada,..

Ginkgo Bioworks Holdings, Inc. (DNA): Investor Outlook and Potential Challenges in Biotechnology

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), a biotechnology company headquartered in Boston, Massachusetts, is making waves in the healthcare sector with its innovative approach to cell..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Unpacking a 38% Upside Potential in the Healthcare Sector

Sonida Senior Living, Inc. (SNDA), a key player in the United States’ healthcare sector, particularly in the medical care facilities industry, has piqued investor interest with..

HealthStream (HSTM) Stock Analysis: A Closer Look at Growth Potential and Analyst Ratings

HealthStream, Inc. (NASDAQ: HSTM), a leading provider of Software-as-a-Service (SaaS) applications for healthcare organizations, has become an intriguing player in the health information services industry. With..

CorMedix Inc. (CRMD) Stock Analysis: Unveiling a Potential 105% Upside in Biotech

CorMedix Inc. (NASDAQ: CRMD) emerges as a compelling player in the biotechnology sector with a primary focus on developing therapeutic solutions for life-threatening diseases. The company,..

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a 62% Potential Upside in the Medical Devices Sector

Delcath Systems, Inc. (NASDAQ: DCTH), a prominent player in the medical devices industry, has been making waves with its innovative approach to treating primary and metastatic..

Butterfly Network, Inc. (BFLY) Stock Analysis: A 42% Upside Potential Amid Rising Revenue Growth

Butterfly Network, Inc. (NASDAQ: BFLY), a pioneering company in the healthcare sector, specifically within the medical devices industry, is making significant strides with its innovative ultrasound..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Assessing a 39% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is carving a niche in the healthcare sector with its focus on rare diseases, a strategic move that has not only..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring the Potential in Biotech Innovation

Anavex Life Sciences Corp. (NASDAQ: AVXL) stands at the forefront of the healthcare sector with a focus on developing treatments for complex central nervous system disorders...

Relay Therapeutics, Inc. (RLAY) Stock Analysis: A Biotech Player with 59% Upside Potential

Relay Therapeutics, Inc. (NASDAQ: RLAY), a clinical-stage precision medicines company, is making waves in the biotechnology sector with its innovative approach to drug discovery. Headquartered in..

Immatics N.V. (IMTX) Stock Analysis: Unraveling a 141.70% Potential Upside for Biotech Investors

Immatics N.V. (NASDAQ: IMTX), a Germany-based clinical-stage biopharmaceutical firm, has caught the attention of investors with its promising pipeline of T cell redirecting immunotherapies aimed at..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds